Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
How is it handled in a lab setting
Major cardiovascular outcome trials include: LEADER trial (liraglutide): Demonstrated a significant reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk SUSTAIN-6 (semaglutide): Showed reduced cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke REWIND (dulaglutide): Confirmed cardiovascular benefits across a broad patient population SELECT trial (semaglutide): Showed reduced MACE in people with obesity without diabetes, though this evidence is not yet fully incorporated into UK labelling [17] These trials consistently found that the modest heart rate increases observed did not translate into adverse cardiovascular outcomes
This calculator shows weekly dose, injection timing (2-3x weekly), injection volume based on concentration, and total vials needed for your protocol
Tirzepatide, a dual GLP-1 and GIP receptor agonist, has shown excellent weight loss results in the SURMOUNT trials but does not yet have equivalent long-term cardiovascular outcomes data published
By inhibiting the NP (natriuretic peptide) system, sacubitril/valsartan increases natriuretic peptides (NPs) levels that, in turn, lead to vasodilation, natriuresis and RAAS inhibition through intracellular cyclic guanosine monophosphate (cGMP)-dependent pathways
Added 100mg Garcinia cambogia fruit extract contains Hydroxy citric acid (HCA) as an active ingredient that suppresses the fat producing enzyme citrate lyase
US$ 24.93
US$ 22.18
US$ 27.08
US$ 28.79
US$ 26.89
